Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies.


Journal

Seminars in radiation oncology
ISSN: 1532-9461
Titre abrégé: Semin Radiat Oncol
Pays: United States
ID NLM: 9202882

Informations de publication

Date de publication:
Jul 2020
Historique:
entrez: 7 6 2020
pubmed: 7 6 2020
medline: 7 9 2021
Statut: ppublish

Résumé

Local and regional recurrences are common following an initial course of radiotherapy, yet management of these recurrences remains a challenge. Reirradiation may be an optimal treatment approach for providing durable tumor control and even offering select patients with locoregional recurrences or new primary tumors a chance of cure, but photon reirradiation can be associated with considerable risks of high grade acute and late toxicities. The high conformality and lack of exit dose with proton therapy offer significant advantages for reirradiation. By decreasing dose to adjacent normal tissues, proton therapy can more safely deliver definitive instead of palliative doses of reirradiation, more safely dose escalate reirradiation treatment, and more safely allow for concurrent systemic therapy in the reirradiation setting. In this case-based analysis, renowned experts in the fields of proton therapy and of reirradiation present cases for which they recently employed proton reirradiation. This manuscript focuses on case studies in patients with lung cancer, head and neck malignancies, and pelvic malignancies. Considerations for when to deliver proton therapy in the reirradiation setting and the pros and cons of proton therapy are discussed, and the existing literature supporting the use of proton reirradiation for these disease sites is assessed.

Identifiants

pubmed: 32503791
pii: S1053-4296(20)30008-4
doi: 10.1016/j.semradonc.2020.02.007
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

253-261

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Charles B Simone (CB)

Department of Radiation Oncology, New York Proton Center and Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: csimone@nyproton.com.

John P Plastaras (JP)

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.

Salma K Jabbour (SK)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ.

Anna Lee (A)

Department of Radiation Oncology, New York Proton Center and Memorial Sloan Kettering Cancer Center, New York, NY.

Nancy Y Lee (NY)

Department of Radiation Oncology, New York Proton Center and Memorial Sloan Kettering Cancer Center, New York, NY.

J Isabelle Choi (JI)

Department of Radiation Oncology, New York Proton Center and Memorial Sloan Kettering Cancer Center, New York, NY.

Steven J Frank (SJ)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Joe Y Chang (JY)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Jeffrey Bradley (J)

Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH